$REPH Recro Pharma, Inc. Insider Trading Week 21/2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Recro Pharma, Inc. in week 21/2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 25 2016 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 6.30 | 7,497 | 47,232 | 2,322,824 | 2.3 M to 2.3 M (-0.32 %) |
| May 25 2016 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 6.30 | 2,503 | 15,769 | 776,131 | 778.6 K to 776.1 K (-0.32 %) |
| May 25 2016 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Buy | P | 6.30 | 2,000 | 12,600 | 2,000 | 0 to 2 K |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 6.45 | 5,008 | 32,326 | 778,634 | 783.6 K to 778.6 K (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 6.45 | 14,992 | 96,770 | 2,330,321 | 2.3 M to 2.3 M (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 6.46 | 1,252 | 8,083 | 783,642 | 784.9 K to 783.6 K (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 6.46 | 3,748 | 24,197 | 2,345,313 | 2.3 M to 2.3 M (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 150 | 1,350 | 784,894 | 785 K to 784.9 K (-0.02 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 450 | 4,050 | 2,349,061 | 2.3 M to 2.3 M (-0.02 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 2,250 | 20,252 | 785,044 | 787.3 K to 785 K (-0.29 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 6,737 | 60,639 | 2,349,511 | 2.4 M to 2.3 M (-0.29 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 1,553 | 13,977 | 787,294 | 788.8 K to 787.3 K (-0.20 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 4,648 | 41,832 | 2,356,248 | 2.4 M to 2.4 M (-0.20 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.01 | 691 | 6,223 | 788,847 | 789.5 K to 788.8 K (-0.09 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.01 | 2,068 | 18,624 | 2,360,896 | 2.4 M to 2.4 M (-0.09 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 3,702 | 33,321 | 789,538 | 793.2 K to 789.5 K (-0.47 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Sell | S | 9.00 | 11,082 | 99,748 | 2,362,964 | 2.4 M to 2.4 M (-0.47 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 6.45 | 5,008 | 32,326 | 778,634 | 783.6 K to 778.6 K (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 6.45 | 14,992 | 96,770 | 2,330,321 | 2.3 M to 2.3 M (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 6.46 | 1,252 | 8,083 | 783,642 | 784.9 K to 783.6 K (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 6.46 | 3,748 | 24,197 | 2,345,313 | 2.3 M to 2.3 M (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 150 | 1,350 | 784,894 | 785 K to 784.9 K (-0.02 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 450 | 4,050 | 2,349,061 | 2.3 M to 2.3 M (-0.02 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 2,250 | 20,252 | 785,044 | 787.3 K to 785 K (-0.29 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 6,737 | 60,639 | 2,349,511 | 2.4 M to 2.3 M (-0.29 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 1,553 | 13,977 | 787,294 | 788.8 K to 787.3 K (-0.20 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 4,648 | 41,832 | 2,356,248 | 2.4 M to 2.4 M (-0.20 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.01 | 691 | 6,223 | 788,847 | 789.5 K to 788.8 K (-0.09 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.01 | 2,068 | 18,624 | 2,360,896 | 2.4 M to 2.4 M (-0.09 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 3,702 | 33,321 | 789,538 | 793.2 K to 789.5 K (-0.47 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | LUDOMIRSKI ABRAHAM | Director | Sell | S | 9.00 | 11,082 | 99,748 | 2,362,964 | 2.4 M to 2.4 M (-0.47 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 6.45 | 5,008 | 32,326 | 778,634 | 783.6 K to 778.6 K (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 6.45 | 14,992 | 96,770 | 2,330,321 | 2.3 M to 2.3 M (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 6.46 | 1,252 | 8,083 | 783,642 | 784.9 K to 783.6 K (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 6.46 | 3,748 | 24,197 | 2,345,313 | 2.3 M to 2.3 M (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 150 | 1,350 | 784,894 | 785 K to 784.9 K (-0.02 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 450 | 4,050 | 2,349,061 | 2.3 M to 2.3 M (-0.02 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 2,250 | 20,252 | 785,044 | 787.3 K to 785 K (-0.29 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 6,737 | 60,639 | 2,349,511 | 2.4 M to 2.3 M (-0.29 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 1,553 | 13,977 | 787,294 | 788.8 K to 787.3 K (-0.20 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 4,648 | 41,832 | 2,356,248 | 2.4 M to 2.4 M (-0.20 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.01 | 691 | 6,223 | 788,847 | 789.5 K to 788.8 K (-0.09 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.01 | 2,068 | 18,624 | 2,360,896 | 2.4 M to 2.4 M (-0.09 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 3,702 | 33,321 | 789,538 | 793.2 K to 789.5 K (-0.47 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Sell | S | 9.00 | 11,082 | 99,748 | 2,362,964 | 2.4 M to 2.4 M (-0.47 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 6.45 | 14,992 | 96,770 | 2,330,321 | 2.3 M to 2.3 M (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 6.46 | 3,748 | 24,197 | 2,345,313 | 2.3 M to 2.3 M (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 6.45 | 5,008 | 32,326 | 778,634 | 783.6 K to 778.6 K (-0.64 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 6.46 | 1,252 | 8,083 | 783,642 | 784.9 K to 783.6 K (-0.16 %) |
| May 23 2016 | REPH | Recro Pharma, Inc. | Nichols Donna | CAO/Controller | Buy | P | 6.48 | 1,140 | 7,387 | 2,340 | 1.2 K to 2.3 K (+95.00 %) |